Showing 2,660 results

Filters Content type: News, Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

New & experimental hepatitis C treatment

'Dallas Buyers' Club' for Hep C treatments under investigation

Editor's pick
Sydney Morning Herald
22 October 2015
Hepatitis & HIV

Sofosbuvir + daclatasvir demonstrates high cure rates for people with HIV and HCV co-infection

News
21 October 2015
Hepatitis C treatment

US study provides 'real world' evidence about which patients with hepatitis C should be prioritised for therapy

News
20 October 2015
Harm reduction

Opioid substitution therapy, especially in combination with needle exchange, reduces transmission of hepatitis C

News
19 October 2015
New & experimental HIV treatments

Studies continue to support tenofovir alafenamide combination pill as it nears US approval

News
19 October 2015
New & experimental hepatitis C treatment

NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4

Editor's pick
Bristol-Myers Squibb press release
16 October 2015
Hepatitis C symptoms & diagnosis

Hepatitis C-related mortality continues to increase in the US

News
16 October 2015
Hepatitis C treatment side-effects

Abacavir/lamivudine could be driving liver damage in ART-treated patients with HIV/HCV co-infection

News
14 October 2015
Hepatitis B

HIV Drugs Provide Added Benefit of Protecting Against Hepatitis B Virus

Editor's pick
Johns Hopkins Medicine
13 October 2015
Hepatitis C treatment

Interferon-free treatment works well for people who inject drugs, but barriers to access remain

News
13 October 2015
Hepatitis C treatment

NYU Research: Development of Severe Liver Damage in Mid/Late-adulthood among People Who Inject Drugs with Chronic HCV

Editor's pick
New York University press release
12 October 2015
Hepatitis C treatment

People who inject drugs should have access to hepatitis C treatment, expert panel recommends

News
7 October 2015
New & experimental hepatitis C treatment

U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs

Editor's pick
Bristol-Myers Squibb
7 October 2015
Hepatitis C treatment

Rising death rates and burden of liver disease requires urgent hepatitis C treatment in people who inject or have injected drugs

Editor's pick
Kirby Institute press release
7 October 2015
Hepatitis C treatment

NYU researchers find development of serious liver damage in mid- to late-adulthood among people who inject drugs with untreated chronic hepatitis C infection

Editor's pick
NYU press release
6 October 2015
Hepatitis B

ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®

Editor's pick
Contravir press release
6 October 2015
Hepatitis C treatment

Treating 5 percent of hepatitis C patients with new drugs would reduce cost and infections, study shows

Editor's pick
USC News
6 October 2015
New & experimental hepatitis C treatment

New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment

News
5 October 2015
Access to healthcare

FixHepC, the buyers club for hepatitis C drug, inundated with inquiries

Editor's pick
Sydney Morning Herald
2 October 2015
Access to healthcare

Hepatitis C drug buyers club aims to set up new source of support

Editor's pick
Sydney Morning Herald
28 September 2015
New & experimental hepatitis C treatment

Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes

Editor's pick
Gilead press release
21 September 2015
People who inject drugs

What We Talk About When We Talk About Hepatitis C

Editor's pick
Huffington Post
18 September 2015
New & experimental hepatitis C treatment

Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Editor's pick
Achillion press release
18 September 2015
Hepatitis C transmission & prevention

Sexual transmission of HCV is increasing among gay and bisexual men with HIV, meta-analysis finds

News
18 September 2015